Axsome Therapeutics (AXSM) Finished Goods (2022 - 2026)

Axsome Therapeutics (AXSM) has 5 years of Finished Goods data on file, last reported at $15.9 million in Q1 2026.

• For the quarter ending Q1 2026, Finished Goods rose 77.28% year-over-year to $15.9 million; the trailing twelve-month figure through Mar 2026 stood at $15.9 million (up 77.28% YoY), and the FY2025 full-year result was $11.3 million, up 25.53% from the prior year.
• Finished Goods rose to $15.9 million in Q1 2026, from $11.3 million in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $15.9 million in Q1 2026 to a low of $1.6 million in Q4 2022.
• A 5-year average of $8.7 million and a median of $9.0 million in 2025 frame the typical range for Finished Goods.
• Across the five-year window, Finished Goods surged 506.48% in 2023 and fell 12.0% in 2025, its largest moves.
• Tracing AXSM's Finished Goods over 5 years: stood at $1.6 million in 2022, then surged by 506.48% to $9.6 million in 2023, then fell by 6.81% to $9.0 million in 2024, then rose by 25.53% to $11.3 million in 2025, then surged by 40.85% to $15.9 million in 2026.
• Business Quant data shows AXSM's Finished Goods at $15.9 million in Q1 2026, $11.3 million in Q4 2025, and $10.3 million in Q3 2025.